Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma

• Status: Unknown status
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Intraocular pressure (IOP) is considered to be the main risk factor for progression of glaucoma and therefore the main target of therapy. Pharmacologic treatment of glaucoma has changed considerably during the last decades due to the introduction of prostaglandin analogues. Three of these are commonly used in North America: latanoprost (Latanoprost T, Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).

There have been several studies to evaluate their effectiveness. The three seem to be equivalent, according to the only study that has compared the molecules. Latanoprost is employed initially, due to its paucity of side effects when compared to the other two analogues. However, if it is not effective, several studies ahve shown that a result is possible using either travoprost or bimatoprost. No study has been conducted to date systematically comparing the three molecules in cases of resistance to latanoprost. In actuality, the investigators patients will receive treatment identical to current practice with the exception of the group continuing with latanoprost. Several studies confirm the benefit of changing prostaglandin analogues if the first has not signficantly decreased the IOP (Palmberg et al. 2004). Each prostaglandin has unique properties which may cause the mechanism of action to vary slightly among patients. (cf. Pharmacological Aspects)

The goal of the study is thus to evaluate the efficaciousness of latanoprost, bimatoprost and travoprost in their IOP-lowering capacity in patients who do not initially respond to latanoprost.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
• Treatments: Bimatoprost; Latanoprost; Travoprost

Criteria

Inclusion Criteria:

• Patients diagnosed with ocular hypertension or primary open-angle glaucoma who have never received treatment.

• Age 18 or older and able to give informed consent

Exclusion Criteria:

• Patients with intraocular inflammation of any etiology

• Patients with advanced glaucoma, defined by severe optic nerve damage and/or visual field deficit.

• Patients having had intraocular surgery in the last 4 weeks

• Patients undergoing treatment with ophthalmic solution of any kind

• Patients unable to give informed consent to participate in the research project,including those suffering from psychiatric illness resulting in impaired judgement

• Monophthalmia or anophthalmia

• Pregnant or nursing patients

• Patients status post ocular surgery, with the exception of cataract extraction surgery